Cargando…

Allogeneic Stem Cell Transplantation with a Novel Reduced Intensity Conditioning Regimen for the Treatment of Patients with Primary Cutaneous T-cell Lymphomas

The prognosis of patients with mycosis fungoides (MF) and Sezary Syndrome (SS) varies greatly, from near normal life expectancy in patients with early stage, to a median survival of less than 2 years for those diagnosed with advanced stage disease. Initial response to treatment is almost always foll...

Descripción completa

Detalles Bibliográficos
Autores principales: Stamouli, Maria, Gkirkas, Konstantinos, Karagiannidi, Aggeliki, Iliakis, Theodoros, Chondropoulos, Spiros, Thomopoulos, Thomas, Nikolaou, Vassiliki, Pappa, Vassiliki, Papadavid, Evangelia, Tsirigotis, Panagiotis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Atlantis Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432398/
https://www.ncbi.nlm.nih.gov/pubmed/34595469
http://dx.doi.org/10.2991/chi.k.210529.001
_version_ 1783751153971888128
author Stamouli, Maria
Gkirkas, Konstantinos
Karagiannidi, Aggeliki
Iliakis, Theodoros
Chondropoulos, Spiros
Thomopoulos, Thomas
Nikolaou, Vassiliki
Pappa, Vassiliki
Papadavid, Evangelia
Tsirigotis, Panagiotis
author_facet Stamouli, Maria
Gkirkas, Konstantinos
Karagiannidi, Aggeliki
Iliakis, Theodoros
Chondropoulos, Spiros
Thomopoulos, Thomas
Nikolaou, Vassiliki
Pappa, Vassiliki
Papadavid, Evangelia
Tsirigotis, Panagiotis
author_sort Stamouli, Maria
collection PubMed
description The prognosis of patients with mycosis fungoides (MF) and Sezary Syndrome (SS) varies greatly, from near normal life expectancy in patients with early stage, to a median survival of less than 2 years for those diagnosed with advanced stage disease. Initial response to treatment is almost always followed by relapse and, finally, most of patients enter a phase of advanced multi-drug resistant disease with a short life expectancy after multiple lines of treatment. Allogeneic stem cell transplantation (allo-SCT) is usually limited to patients with advanced disease resistant to multiple treatments. Retrospective registry-based studies have shown increased Non-relapse Mortality (NRM) rates in patients with poor performance status, as well as in patients treated with myeloablative conditioning regimens. Another major limitation of allo-SCT is the increased relapse rate which occurs in nearly 50% of the cases, and is probably due to the fact that only heavily pretreated patients with advanced disease are referred for allo-SCT. Due to the paucity of data, the ideal conditioning regimen which will provide the maximum therapeutic benefit without the cost of increased NRM is not currently known. In this article we present our experience with a novel regimen in the treatment of patients with advanced MF/SS.
format Online
Article
Text
id pubmed-8432398
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Atlantis Press
record_format MEDLINE/PubMed
spelling pubmed-84323982021-09-29 Allogeneic Stem Cell Transplantation with a Novel Reduced Intensity Conditioning Regimen for the Treatment of Patients with Primary Cutaneous T-cell Lymphomas Stamouli, Maria Gkirkas, Konstantinos Karagiannidi, Aggeliki Iliakis, Theodoros Chondropoulos, Spiros Thomopoulos, Thomas Nikolaou, Vassiliki Pappa, Vassiliki Papadavid, Evangelia Tsirigotis, Panagiotis Clin Hematol Int Research Article The prognosis of patients with mycosis fungoides (MF) and Sezary Syndrome (SS) varies greatly, from near normal life expectancy in patients with early stage, to a median survival of less than 2 years for those diagnosed with advanced stage disease. Initial response to treatment is almost always followed by relapse and, finally, most of patients enter a phase of advanced multi-drug resistant disease with a short life expectancy after multiple lines of treatment. Allogeneic stem cell transplantation (allo-SCT) is usually limited to patients with advanced disease resistant to multiple treatments. Retrospective registry-based studies have shown increased Non-relapse Mortality (NRM) rates in patients with poor performance status, as well as in patients treated with myeloablative conditioning regimens. Another major limitation of allo-SCT is the increased relapse rate which occurs in nearly 50% of the cases, and is probably due to the fact that only heavily pretreated patients with advanced disease are referred for allo-SCT. Due to the paucity of data, the ideal conditioning regimen which will provide the maximum therapeutic benefit without the cost of increased NRM is not currently known. In this article we present our experience with a novel regimen in the treatment of patients with advanced MF/SS. Atlantis Press 2021-06-12 /pmc/articles/PMC8432398/ /pubmed/34595469 http://dx.doi.org/10.2991/chi.k.210529.001 Text en © 2021 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ).
spellingShingle Research Article
Stamouli, Maria
Gkirkas, Konstantinos
Karagiannidi, Aggeliki
Iliakis, Theodoros
Chondropoulos, Spiros
Thomopoulos, Thomas
Nikolaou, Vassiliki
Pappa, Vassiliki
Papadavid, Evangelia
Tsirigotis, Panagiotis
Allogeneic Stem Cell Transplantation with a Novel Reduced Intensity Conditioning Regimen for the Treatment of Patients with Primary Cutaneous T-cell Lymphomas
title Allogeneic Stem Cell Transplantation with a Novel Reduced Intensity Conditioning Regimen for the Treatment of Patients with Primary Cutaneous T-cell Lymphomas
title_full Allogeneic Stem Cell Transplantation with a Novel Reduced Intensity Conditioning Regimen for the Treatment of Patients with Primary Cutaneous T-cell Lymphomas
title_fullStr Allogeneic Stem Cell Transplantation with a Novel Reduced Intensity Conditioning Regimen for the Treatment of Patients with Primary Cutaneous T-cell Lymphomas
title_full_unstemmed Allogeneic Stem Cell Transplantation with a Novel Reduced Intensity Conditioning Regimen for the Treatment of Patients with Primary Cutaneous T-cell Lymphomas
title_short Allogeneic Stem Cell Transplantation with a Novel Reduced Intensity Conditioning Regimen for the Treatment of Patients with Primary Cutaneous T-cell Lymphomas
title_sort allogeneic stem cell transplantation with a novel reduced intensity conditioning regimen for the treatment of patients with primary cutaneous t-cell lymphomas
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432398/
https://www.ncbi.nlm.nih.gov/pubmed/34595469
http://dx.doi.org/10.2991/chi.k.210529.001
work_keys_str_mv AT stamoulimaria allogeneicstemcelltransplantationwithanovelreducedintensityconditioningregimenforthetreatmentofpatientswithprimarycutaneoustcelllymphomas
AT gkirkaskonstantinos allogeneicstemcelltransplantationwithanovelreducedintensityconditioningregimenforthetreatmentofpatientswithprimarycutaneoustcelllymphomas
AT karagiannidiaggeliki allogeneicstemcelltransplantationwithanovelreducedintensityconditioningregimenforthetreatmentofpatientswithprimarycutaneoustcelllymphomas
AT iliakistheodoros allogeneicstemcelltransplantationwithanovelreducedintensityconditioningregimenforthetreatmentofpatientswithprimarycutaneoustcelllymphomas
AT chondropoulosspiros allogeneicstemcelltransplantationwithanovelreducedintensityconditioningregimenforthetreatmentofpatientswithprimarycutaneoustcelllymphomas
AT thomopoulosthomas allogeneicstemcelltransplantationwithanovelreducedintensityconditioningregimenforthetreatmentofpatientswithprimarycutaneoustcelllymphomas
AT nikolaouvassiliki allogeneicstemcelltransplantationwithanovelreducedintensityconditioningregimenforthetreatmentofpatientswithprimarycutaneoustcelllymphomas
AT pappavassiliki allogeneicstemcelltransplantationwithanovelreducedintensityconditioningregimenforthetreatmentofpatientswithprimarycutaneoustcelllymphomas
AT papadavidevangelia allogeneicstemcelltransplantationwithanovelreducedintensityconditioningregimenforthetreatmentofpatientswithprimarycutaneoustcelllymphomas
AT tsirigotispanagiotis allogeneicstemcelltransplantationwithanovelreducedintensityconditioningregimenforthetreatmentofpatientswithprimarycutaneoustcelllymphomas